atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder

Stock Information for Atai Beckley N.V

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Atai Beckley N.V

AtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthening Intellectual Property Portfolio
Enhanced Fortifies Executive Leadership Team & Board of Directors
AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London
AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression
atai Life Sciences and Beckley Psytech Announce the Successful Completion of Their Strategic Combination to Create AtaiBeckley, a Global Leader in Transformative Mental Health Therapies
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
atai Life Sciences Announces Pricing of Public Offering of Common Shares

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.